Last updated: July 29, 2026
Cefoxitin sodium is a mature, off-patent parenteral cephamycin antibiotic used for surgical prophylaxis and intra-abdominal/gynecologic infections. Current market dynamics are dominated by hospital formulary decisions, generic pricing, and supply reliability rather than active clinical development. No material late-stage clinical-trial pipeline or drug-specific, FDA-regulatory exclusivity tail is evident for cefoxitin sodium based on public, drug-wide signals.
Market thesis (high level)
- Demand: tied to surgical volumes, antimicrobial stewardship protocols, and availability of multiple equivalent cefazolin/cefotetan alternatives.
- Pricing: structurally compressed by generics and compendial usage; revenue growth is limited to volume shifts and contract procurement.
- Risk: supply constraints and drug shortages can temporarily improve pricing, but sustained premium is unlikely without a proprietary formulation, platform delivery system, or new indication.
- Pipeline: no clear evidence of a modern, registrational program that would materially extend exclusivity or create a new branded commercial cycle.
What is cefoxitin sodium used for and what are the current clinical development signals?
Featured snippet: Cefoxitin sodium is used for surgical prophylaxis and susceptible bacterial infections, and its clinical development profile is largely inactive versus newer beta-lactams.
Cefoxitin sodium (a cephamycin-class beta-lactam) is administered intravenously or intramuscularly and is positioned in hospital practice for:
- Surgical prophylaxis (notably in colorectal and gynecologic procedures in many formularies)
- Intra-abdominal and pelvic infections caused by susceptible organisms
- Skin/skin-structure and other site infections depending on local susceptibility patterns
Clinical-trials landscape (signal-based)
Public registries and sponsor activity for cefoxitin sodium show a mature status with limited investment in new registrational endpoints. Most trial activity in the cefoxitin space is historical, centered on:
- Susceptibility testing and comparative microbiology
- Pharmacokinetic/pharmacodynamic characterization in special populations
- Short-form clinical observation studies tied to stewardship or resistance surveillance
What this means commercially
- No “pipeline tail” that typically supports premium pricing.
- Market share is protected by contracting and inclusion in hospital pathways, not by ongoing Phase 3 outcomes.
Are there any active or recent clinical trials for cefoxitin sodium?
Featured snippet: There is no clear, ongoing late-stage (Phase 3) registrational program that would change exclusivity or redefine standard of care.
Search-intent answer (what to look for in registries)
For an antibiotic like cefoxitin sodium, active trials worth commercial attention are usually:
- Phase 3 comparative trials against an established prophylaxis regimen
- New indication trials with clinical endpoints (not only microbiology)
- FDA-relevant formulation trials that seek approval for a new route, concentration, or device-based delivery
Current posture
For cefoxitin sodium, the practical expectation is:
- If trials exist, they skew toward stewardship, observational cohorts, or microbiology surveillance.
- If trials exist, they are unlikely to create a new FDA approval hook that extends commercial rights beyond the generic baseline.
What is the FDA status of cefoxitin sodium and is it listed in the Orange Book?
Featured snippet: Cefoxitin sodium is an approved drug with generics widely available; Orange Book listing exists for approved NDA and ANDAs, but cefoxitin’s commercial rights are driven by generic competition rather than exclusivity.
How Orange Book status typically maps to this category
For older antibiotics:
- Brands, if any, are generally off exclusivity.
- ANDA listings dominate.
- Patent families, if they exist in Orange Book, tend to be composition/packaging or method claims that lapse or are no longer enforceable.
Commercial consequence
Once multiple ANDA products are authorized, market access is mostly procurement-led. Patent-driven leverage is limited unless a formulation-specific patent remains in force for a particular dosage/strength.
What patents protect cefoxitin sodium and when do they expire?
Featured snippet: Cefoxitin sodium is expected to be largely off-patent for composition-of-matter, with any remaining patent protection concentrated in narrow formulation, manufacturing, or packaging claims.
Patent estate practical interpretation for hospitals and generic entrants
In mature antibiotics, the patent estate often collapses into:
- Old composition-of-matter terms expired long ago
- Narrow formulation/process patents that may affect specific dosage forms
- Impurity specification or manufacturing method claims that are hard to enforce across all generics
Bottom line for market outlook
- Patent expiration is not a meaningful near-term event.
- Competitive entry is already established; incremental launches are more likely driven by supply dynamics than by legal timing.
What is the Paragraph IV and patent-challenge risk for cefoxitin sodium generics?
Featured snippet: Paragraph IV-driven entry is less likely to be the primary determinant of near-term supply or price changes for a fully generic antibiotic.
Why Paragraph IV is not the main lever
- When multiple ANDAs already exist, remaining legal runway is small.
- Generic competition tends to be continuous via ANDA maintenance and incremental supply expansions.
What can still matter
- Litigation outcomes can affect specific manufacturers or specific strengths.
- Consent decrees and settlement outcomes can constrain a subset of entrants, even in a generally off-patent category.
How many generic cefoxitin sodium products are on the market and who are the key manufacturers?
Featured snippet: The cefoxitin sodium market is served by multiple authorized generic manufacturers; hospital procurement is the primary driver of which brands win.
Because this request requires Orange Book/NDC-level enumeration and citation to specific listings, a complete, accurate “who’s on the market” count cannot be produced from the information currently provided in the prompt.
What is the cefoxitin sodium market size, revenue drivers, and growth rate projection?
Featured snippet: Growth is constrained by commoditization; volume and institutional contracting drive revenue more than unit price.
Revenue model for mature hospital antibiotics
- Unit price: anchored to competitive generic tender pricing.
- Volume: tied to surgical case volumes and infection incidence.
- Utilization: shaped by antimicrobial stewardship, antibiogram patterns, and pathway adoption.
Near-term growth projection (directional)
- Base case: low single-digit annual growth driven by procedural volume and replacement demand.
- Upside case: temporary pricing improvement during shortages or supplier disruptions.
- Downside case: pathway substitution toward other prophylaxis regimens and more stewardship-driven narrowing.
Key variables that swing utilization
- Surgical mix shifts (colorectal, gynecology, obstetric)
- Local resistance patterns (Enterobacterales and anaerobe susceptibility)
- Hospital formulary preference versus cefotetan/cefazolin alternatives
- Shortage status of cefoxitin sodium or interchangeables
What competitive threats does cefoxitin sodium face from other beta-lactams or alternatives?
Featured snippet: Substitution risk comes from other perioperative and intra-abdominal antibiotics with comparable coverage and procurement advantages.
Competitive set (functional)
- Cephalosporins used for prophylaxis (e.g., cefazolin in many pathways)
- Cephalosporin alternatives used in intra-abdominal infections (agent-specific)
- Beta-lactam/beta-lactamase inhibitor combinations depending on hospital protocol
- Carbapenems reserved for resistant cases, limiting share but influencing stewardship-driven shifts
Why switching happens
- Procurement economics and contracting
- Packaging and dosing convenience
- Institutional experience with local adverse event profiles and nursing workflow
Implication
Even with stable overall surgical prophylaxis demand, cefoxitin’s share can move within the class based on tenders and guideline adoption.
What formulation and manufacturing/IP barriers exist for cefoxitin sodium supply?
Featured snippet: The main barrier is manufacturing robustness and regulatory compliance rather than active patent exclusivity.
Key practical constraints for sterile injectables:
- Sterility assurance, stability, and quality control across batches
- Facility capability for lyophilized or solution forms (depending on the product)
- Regulatory inspection outcomes impacting release timelines
- Raw material supply continuity and cost volatility
Market effect
- Supply disruptions can temporarily lift prices.
- Normalization returns pricing to tender-set levels.
How does cefoxitin sodium compare with cefotetan and other prophylaxis regimens?
Featured snippet: Cefoxitin sodium competes in the same institutional prophylaxis arena but is primarily selected through formulary pathways and procurement rather than differentiation.
Comparison axes hospitals use
- Anaerobe coverage appropriateness for procedure types
- Local antibiogram alignment
- Dosing schedule convenience
- Total cost of therapy under group purchasing organization (GPO) contracts
- Reported tolerability and adverse event considerations
Commercial translation
A weak differentiation profile means cefoxitin’s market performance tracks the procurement and shortage cycle more than clinical breakthroughs.
When does cefoxitin sodium lose exclusivity and what does that mean for generic launch timing?
Featured snippet: Exclusivity for cefoxitin sodium is effectively already exhausted given the extensive generic availability.
Practical “timing” view
- Late-stage exclusivity expirations are not a relevant near-term catalyst.
- Competitive entry timing is instead driven by:
- ANDA approval throughput
- Supplier scaling capacity
- Procurement tenders and awarded contracts
- Shortage-driven substitution effects
What settlement agreements or FDA regulatory actions affect cefoxitin sodium?
Featured snippet: For a mature generics-dense antibiotic, the most common commercial impacts come from shortages, consent decrees specific to individual entrants, and FDA inspection-driven supply disruptions.
A complete litigation and settlement mapping requires case-specific docket and Orange Book legal status data that is not contained in the prompt.
What generic entry risks exist for cefoxitin sodium (biosimilar risk, market access, and exclusivity barriers)?
Featured snippet: Biosimilar risk does not apply; generic entry risk is mostly regulatory/CMC and supply execution rather than legal exclusivity.
Entry risk categories
- CMC readiness for sterile injectable manufacturing
- Bioequivalence demonstration sufficiency (typical for generic antibiotics)
- Stability and container-closure compatibility
- Ability to secure supply for raw materials and maintain consistent potency
- Timeliness of release and distribution logistics
Market access risk
- Even after regulatory approval, formulary and contract access can lag.
- Incumbent supplier relationships can keep new entrants off shortlists.
Commercial projection: 2026 to 2031 for cefoxitin sodium
Featured snippet: Expect stable demand with low-to-mid single-digit revenue variability driven by volume and contract pricing, with shortage episodes creating short-term spikes.
Base-case projection (directional)
- Revenue: flat to low growth (institutional procurement, stable volume)
- Share: shiftable within beta-lactam prophylaxis alternatives
- Pricing: tender-set, with occasional shortage-driven increases
Upside scenarios
- Antibiotic shortage in cefoxitin or interchangeables increases temporary share capture
- Expanded adoption in surgical pathways due to stewardship protocols favoring cefoxitin’s spectrum
Downside scenarios
- Broad switching to preferred prophylaxis options under new pathways
- Persistent supply constraints at multiple manufacturers cause utilization to drop rather than shift upward
Key Takeaways
- Cefoxitin sodium is a mature, broadly generic antibiotic with market outcomes driven by hospital procurement, utilization pathways, and supply reliability.
- Clinical development appears limited in a way that would not materially extend exclusivity or reprice the market through a registrational program.
- Patent-expiration timing is not a near-term catalyst; competitive dynamics are already structured around established generics and contract awards.
- Growth projection is constrained; revenue variability is most sensitive to surgical volume trends and shortage episodes rather than to pipeline milestones.
FAQs
- What are the most common hospital uses for cefoxitin sodium in surgical prophylaxis?
- Does cefoxitin sodium have any remaining Orange Book exclusivities that could delay generic competition?
- How do shortages of cefoxitin sodium typically affect tender pricing and distribution?
- What cefoxitin sodium generics are typically selected through GPO contracting and hospital formularies?
- How does stewardship influence cefoxitin sodium utilization versus cefazolin or cefotetan?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed 2026).
- ClinicalTrials.gov. cefoxitin sodium search results. (accessed 2026).
